---
figid: PMC7322178__gr5
figtitle: Metabolic impact of tyrosine kinase inhibitor (TKI) administration
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC7322178
filename: gr5.jpg
figlink: pmc/articles/PMC7322178/figure/fig5/
number: F5
caption: Metabolic impact of tyrosine kinase inhibitor (TKI) administration. The inhibition
  of different receptor tyrosine kinase (RTK) alters all cancer hallmarks. Dovitinib,
  Imatinib, Gefitinib, Erlotinib and Capmatinib reduce glycolytic pathway, while Sorafenib
  promoted mitochondrial dysfunction. Lipid synthesis and protein synthesis were profoundly
  altered by TKIs. ETC; Electron transport chain.
papertitle: Integrated molecular signaling involving mitochondrial dysfunction and
  alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer.
reftext: María A. Rodríguez-Hernández, et al. Redox Biol. 2020 Sep;36:101510.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9021125
figid_alias: PMC7322178__F5
figtype: Figure
redirect_from: /figures/PMC7322178__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7322178__gr5.html
  '@type': Dataset
  description: Metabolic impact of tyrosine kinase inhibitor (TKI) administration.
    The inhibition of different receptor tyrosine kinase (RTK) alters all cancer hallmarks.
    Dovitinib, Imatinib, Gefitinib, Erlotinib and Capmatinib reduce glycolytic pathway,
    while Sorafenib promoted mitochondrial dysfunction. Lipid synthesis and protein
    synthesis were profoundly altered by TKIs. ETC; Electron transport chain.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Pvr
  - adp
  - Ret
  - reticulated
  - reti
  - rets
  - ATPsynbeta
  - Atpalpha
  - ras
  - Ras64B
  - Ras85D
  - Mtor
  - Tor
  - ber
  - Abl
  - Abi
  - ci
  - CycE
  - cyc
  - cv
  - PDGFRB
  - PDGFRA
  - EGFR
  - KDR
  - FLT1
  - FLT4
  - WDTC1
  - RET
  - ATP8A2
  - KRAS
  - HRAS
  - NRAS
  - MTOR
  - ERBB2
  - ABL1
  - MTTP
  - DSP-AS1
  - ABL2
  - C2
  - Axitinib
  - Afatinib
  - Canertinib
  - Axitinib Leflunomide
  - Dasatinib Nilotinib
  - Dovitinib
  - Lenvatinib
  - Pazopanib
  - Regorafenib
  - Semaxinib
  - Sapmatinib
  - Erlotinib
  - Gefitinib
  - Dovitinib Regorafenib
  - Imatinib Sorafenib
  - Lenvatinib Sunitinib
  - Lapatinib
  - Osimertinib
  - Imatinib
  - Sorafenib
  - Sunitinib
  - Vandetanib
  - Capmatinib
  - Cabozantinib
  - Crizotinib
  - Glucose
  - ADP
  - Pentose phosphate ATP
  - Neratinib
  - Aleetinib
  - Amino acids
  - Brigatinib
  - Lactate
  - H
  - Bosutinib
  - Dasatinib
  - Acetyl
  - TCA
  - Nilotinib
  - Oxalacetate
  - Ponatinib
  - Citrate
  - ketoglutarate
---
